Search
SOLACI Congress
HomeFile

File

View Category
Other

Tricuspid Regurgitation, TriBicaval Registry

Tricuspid regurgitation (TR) is a condition whose prevalence is expected to increase in the coming years. Surgery...
Dr. Carlos Fava -
Learn More
Coronary disease

IVI-Guided PCI vs Coronary Artery Bypass Surgery in Left Main Coronary or Multivessel Disease

Several randomized clinical trials have demonstrated the superiority of coronary artery bypass grafting (CABG) over percutaneous coronary...
Dr. Andrés Rodríguez -
Learn More
Mitral valve

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it...
Dr. Carlos Fava -
Learn More
Antithrombotic Anticoagulants

ESC 2025 | HI-PRO: Extended Apixaban for Recurrence Prevention in Provoked DVT/PE

Patients with provoked venous thromboembolism (VTE) usually discontinue anticoagulation after 3 to 6 months. However, in the...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

The routine use of beta-blockers after acute myocardial infarction (AMI) has been a historical recommendation based on...
Dr. Omar Tupayachi -
Learn More
Structural Heart Disease

ESC 2025 | DOUBLE-CHOICE: Anesthesia Strategies and Self-Expanding Valves in TAVI

TAVI has become the predominant treatment for severe aortic stenosis. The DOUBLE-CHOICE trial analyzed two key aspects:...
Dr. Omar Tupayachi -
Learn More
Coronary disease

ESC 2025 | DIGIT-HF: Digitoxin in Heart Failure with Reduced Ejection Fraction

Heart failure with reduced ejection fraction (HFrEF) continues to represent a clinical challenge despite advances in pharmacological...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

ESC 2025 | What Should We Do With Beta-Blockers Post-MI in Patients With Preserved LVEF?

The evidence supporting the use of beta-blockers after myocardial infarction (MI) is strong in patients with ventricular...
Dr. Juan Manuel Pérez -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Tricuspid Regurgitation, TriBicaval Registry

Dr. Carlos Fava - 0
Tricuspid regurgitation (TR) is a condition whose prevalence is expected to increase in the coming years. Surgery presents important challenges and is associated with...

IVI-Guided PCI vs Coronary Artery Bypass Surgery in Left Main Coronary or Multivessel Disease

Dr. Andrés Rodríguez - 0
Several randomized clinical trials have demonstrated the superiority of coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) in patients with left main...

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Dr. Carlos Fava - 0
Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it is often overlooked and some analyses have...

Institutional News

Watch again – New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology

solaci - 0
You can now watch our webinar on “New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology”, held via Zoom on...

ESC 2025: Results of the NEO-MINDSET study — exclusive presentation and analysis with Dr. Pedro Lemos

solaci - 0
Following the presentation of the NEO-MINDSET study in the Late Breaking Clinical Trials sessions at the European Society of Cardiology Congress (ESC 2025), Dr....

SOLACI Webinar – New Guidelines for the Management of Valvular Heart Disease: Implications for Interventional Cardiology

solaci - 0
A new SOLACI virtual scientific event is coming up as part of the scientific coverage of the ESC 2025 Congress. This session will focus on...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy